Abstract-Intracellular Ca 2ϩ ([Ca 2ϩ ] i ) homeostasis regulates vascular smooth muscle tone, and alteration in [Ca 2ϩ ] i handling is associated with the development and establishment of hypertension. We have previously established in the spontaneously hypertensive rat (SHR) that virally mediated delivery of angiotensin II type 1 receptor antisense (AT 1 R-AS) prevents the development of high blood pressure and some pathophysiology associated with hypertension for 120 days. In light of this, our objectives in this study were to determine whether AT 1 R-AS gene therapy (1) could have a longer duration in the prevention of hypertension and (2) Key Words: angiotensin II Ⅲ arterioles Ⅲ calcium, intracellular Ⅲ Ca 2ϩ current Ⅲ excitation-contraction coupling Ⅲ gene therapy E ssential hypertension is characterized by normal cardiac output and an increase in total peripheral resistance. 1 Hypertension is one of the most important risk factors for stroke, congestive heart failure, myocardial infarction, endstage renal diseases, and peripheral vascular disease. 2-4 Studies from the last 2 decades have established that both circulating and tissue renin-angiotensin systems (RAS) are important, that their coordinated interaction is essential in the regulation of blood pressure, and that they play a key role in the development, establishment, and maintenance of hypertension. 2, 5, 6 The relevance of the RAS to blood pressure control is further supported by reports that various genes that encode renin, angiotensinogen, angiotensin-converting enzyme (ACE), and the angiotensin II type 1 receptor (AT 1 R) have been associated with hypertension in both human and animal models. 7-9 Additionally, interruption in the expression of the RAS attenuates high blood pressure and other pathophysiological aspects of hypertension. 4, 10, 11 In fact, blockade of the RAS has become a well-accepted treatment for Angdependent hypertension and congestive heart failure. 11 Because ACE inhibition and AT 1 R blockade are standard means to treat hypertension and because AT 1 R encoding gene polymorphism is coupled with hypertension in both humans and in animal models of hypertension, 6,9 it would appear only logical that AT 1 R is an important target in the management of high blood pressure. Although major strides have been made in developing drugs that interfere with either angiotensin II (Ang II) formation or its action toward the management of Ang-dependent hypertension, there is neither a long-term preventive measure nor a cure for this disease.
] i handling is associated with the development and establishment of hypertension. We have previously established in the spontaneously hypertensive rat (SHR) that virally mediated delivery of angiotensin II type 1 receptor antisense (AT 1 R-AS) prevents the development of high blood pressure and some pathophysiology associated with hypertension for 120 days. In light of this, our objectives in this study were to determine whether AT 1 R-AS gene therapy (1) could have a longer duration in the prevention of hypertension and (2) would attenuate the alterations in renal vascular Ca 2ϩ homeostasis and therefore vasoconstriction, characteristics of hypertension. Intracardiac delivery of AT 1 R-AS in neonates prevented the development of hypertension in SHR for at least 210 days. At this time, untreated SHR renal resistance arterioles showed a significantly enhanced contractile response to KCl and angiotensin II (Ang II) when compared with normotensive Wistar-Kyoto rats. In addition, L-type Ca 2ϩ current density and Ang II-dependent increases in [Ca 2ϩ ] i were significantly increased in cells dissociated from renal resistance arterioles of the untreated SHR. AT 1 R-AS treatment prevented all of the above vascular alterations associated with the hypertensive state in SHR. Finally, Western blot analysis of L-type Ca 2ϩ channel (␣ 1C ) protein levels in renal resistance arterioles of untreated SHR showed no significant difference when compared with control. These results are novel and demonstrate that viral-mediated delivery of AT 1 R-AS not only attenuates the development of hypertension on a long-term basis but prevents changes in renal vascular Ca 2ϩ homeostasis associated with the disease. Key Words: angiotensin II Ⅲ arterioles Ⅲ calcium, intracellular Ⅲ Ca 2ϩ current Ⅲ excitation-contraction coupling Ⅲ gene therapy E ssential hypertension is characterized by normal cardiac output and an increase in total peripheral resistance. 1 Hypertension is one of the most important risk factors for stroke, congestive heart failure, myocardial infarction, endstage renal diseases, and peripheral vascular disease. [2] [3] [4] Studies from the last 2 decades have established that both circulating and tissue renin-angiotensin systems (RAS) are important, that their coordinated interaction is essential in the regulation of blood pressure, and that they play a key role in the development, establishment, and maintenance of hypertension. 2, 5, 6 The relevance of the RAS to blood pressure control is further supported by reports that various genes that encode renin, angiotensinogen, angiotensin-converting enzyme (ACE), and the angiotensin II type 1 receptor (AT 1 R) have been associated with hypertension in both human and animal models. [7] [8] [9] Additionally, interruption in the expression of the RAS attenuates high blood pressure and other pathophysiological aspects of hypertension. 4, 10, 11 In fact, blockade of the RAS has become a well-accepted treatment for Angdependent hypertension and congestive heart failure. 11 Because ACE inhibition and AT 1 R blockade are standard means to treat hypertension and because AT 1 R encoding gene polymorphism is coupled with hypertension in both humans and in animal models of hypertension, 6, 9 it would appear only logical that AT 1 R is an important target in the management of high blood pressure. Although major strides have been made in developing drugs that interfere with either angiotensin II (Ang II) formation or its action toward the management of Ang-dependent hypertension, there is neither a long-term preventive measure nor a cure for this disease.
The most widely used animal model for studying human essential hypertension is the spontaneously hypertensive rat (SHR). Pharmacological intervention has been relatively successful in normalizing the elevation in blood pressure associated with hypertension. However, the assumption that reduction of blood pressure will totally reverse hypertensioninduced pathophysiological changes remains unclear. Several animal studies suggest that gene therapy would be useful in the treatment of hypertension. Olivero et al 12 have shown that disruption of AT 1 R expression in mice causes blunting of pressor responses of Ang II. Phillips et al 13 have used antisense oligonucleotides for the AT 1 R in the brain to reduce high blood pressure in SHR on a short-term basis. Recently, we have established that retrovirally mediated delivery of AT 1 R antisense (AT 1 R-AS) attenuates the development of high blood pressure on a long-term basis (up to 120 days) as well as prevents some of the pathophysiological alterations observed with the disease (eg, endothelial dysfunction, decreased K ϩ channel activity, increased heart weight, and increased cardiac and vascular fibrosis and necrosis) while having no inflammatory response. 14 However, a more important pathophysiological alteration, the prevention of changes in cellular Ca 2ϩ handling and therefore the level of vascular tone, has yet to be investigated.
Alterations in cellular Ca 2ϩ homeostasis using 45 Ca 2ϩ flux, fluorometric, and patch-clamp measurements in large conduit SHR arteries and cells have been described. 15 Renal transplant studies have suggested that the genetic defect in a proportion of the cases with essential hypertension is expressed in the kidney. 16 Therefore, the resistance arterioles of the kidney are an important vasculature bed to study because alterations in renal blood flow are known to influence fluid volume regulation, the secretion of a number of important neurohumoral substances, and arteriolar resistance, which may be involved in the etiology or maintenance of hypertension. Our objective in this study was to determine whether this attenuation of high blood pressure was associated with the prevention of altered Ca 2ϩ handling in cells from renal resistance arterioles induced by the hypertensive state.
Methods

Preparation of Viral Particles Containing AT 1 R-AS
A retroviral vector, LNSV, was used to deliver AT 1B R-AS into the rats as previously described. 14 Briefly, the AT 1B R-AS was cloned in the LNSV vector. It was transfected to packaging cell line PA317 (American Type Culture Collection). After selection by neomycin, the medium containing viral particles that expressed AT 1B R-AS (LNSV-AT 1 R-AS) was collected and used for all animal experiments. Viral particles that did not contain AT 1B R-AS (LNSV) were also prepared by the above protocol and used as a control. The AT 1 R-AS is believed to be specific for the AT 1 R because delivery of missense had no effect on AT 1 R number or the actions of Ang II in Wistar-Kyoto rats (WKY) or SHR. 14, [17] [18] [19] 
Animals and Experimental Protocols
Five-day-old WKY and SHR were divided into 3 treatment groups: vehicle (control), virus alone (LNSV), or virus containing AT 1 R-AS (LNSV-AT 1 R-AS). The treatments were injected directly into the left ventricle of the heart under methoxyflurane anesthesia (metofane, Pitmin-Moore). One bolus of 5ϫ10 10 plaque-forming units of viral particles in 10 L of physiological saline was used per animal. There was a 95% survival rate at 24 to 48 hours after viral administration. Mean blood pressure was measured through an indwelling catheter implanted in the carotid artery using a Digi-Med blood pressure analyzer (Micro-Med) essentially as described. 14 All animal protocols are in accordance with the University of Florida institutional guidelines (IACUC approval 4138 and 5236).
Smooth Muscle Cell Isolation
Renal vascular smooth muscle cells were dissociated as previously described. 14, 20 Male rats were killed by decapitation, and the right and left kidneys were removed and placed in cold oxygenated (95% O 2 -5% CO 2 ) physiological saline solution (PSS). Renal resistance arterioles were identified as the fifth to sixth branch distal to the renal artery, cut into small pieces, and subsequently resuspended in Ca 2ϩ -free PSS digestion buffer for 20 to 30 minutes at 37°C. The Ca 2ϩ -free PSS digestion buffer contained (in mg/15 mL) collagenase (151 U/mg Worthington Biochemical Corp) 4.5, bovine serum albumin (BSA) 30, trypsin inhibitor 30, ATP (sodium salt) 1.7, and protease (type XXIV, Sigma Chemical Co) 1.5. After the digestion, the pieces were gently triturated until a large number of elongated smooth muscle cells were observed. The isolated cells were collected and stored at 4°C until use.
Current Recording and Analysis
Single cells were voltage-clamped, and membrane currents were measured using the whole-cell patch-clamp technique. 14, 20 Data analysis was performed with pCLAMP 6.0 software (Axon Instruments). All experiments were performed at room temperature. 
Tension Measurements
Rat renal resistance arteriole ring segments (1.5 mm long) were mounted onto 2 triangular tungsten wires (35 m in diameter) and hung vertically in an isolated organ chamber (5 mL) as previously described. 14 The bath was maintained at 37°C in PSS.
[Ca 2؉ ] i Measurement [Ca 2ϩ ] i was measured in dissociated renal resistance arteriolar cells using epifluorescence microscopy. Briefly, the cells were loaded with fura 2 by incubation with 5 mol/L membrane-permeable fura 2 acetoxymethylester (fura 2-AM dissolved in 1 mmol/L DMSO stock) for 30 minutes at 37°C. The cells were illuminated alternately with UV light of 340 and 380 nm wavelength using an IonOptix chopper-based, electronically controlled, dual-excitation imaging fluorescence system. Cell fluorescence (emitted light) was collected through a 510-nm barrier filter before acquisition by a photomultiplier tube. The fluorescence signals, F 340 and F 380 , were background subtracted during the experiment. The mean change F 340 and F 380 ratios are graphed, which gives a relative indication in the changes observed in [Ca 2ϩ ] i . The R min and R max of WKY and SHR cells treated with and without virus is not significantly different.
Western Blot Analysis
Renal resistance arterioles were snap-frozen with liquid nitrogen. To isolate proteins, 0.1 g of tissue was homogenized in 2.0 mL of cold Tris-HCl buffer containing 2.5 mg/mL leupeptin and 4 mg/mL calpain inhibitors, pH 7.4. The suspension was centrifuged at 30 000g for 20 minutes at 4°C. The resultant pellet was resuspended in the above solution and recentrifuged. This pellet was resuspended in 1.2% digitonin, 300 mmol/L KCl, 150 mmol/L NaCl, 10 mmol/L NaPO 4 , pepstatin A (0.1 g/mL), leupeptin (0.1 g/mL), aprotinin (0.1 g/mL), AESFB (0.02 mmol/L), benzamidine (0.01 mg/mL), and calpain (0.8 g/mL), pH 7.4. The protein concentration in the supernatant was determined by Bio-Rad assay using BSA for the standard curve.
For immunoblotting, 20 g protein was denatured with Laemmli's sample buffer in a boiling water bath for 3 minutes. Each mixture was electrophoresed in 4% to 15% SDS-polyacrylamide gel and transferred onto nitrocellulose. The membrane was blocked with 10% nonfat dried milk in PBST-BSA for 1 hour followed by incubation overnight at 4°C with either anti-␤-actin (1:100, Sigma) or anti-␣ 1C Ca 2ϩ channel protein (1:1000, Alamone Labs). Proteinbound antibody was detected by incubation of the membrane with horseradish peroxidase-labeled secondary antibody (1:50 000, Jackson ImmmunoResearch Laboratory), enhanced by chemiluminescent assay reagents, and recognized by exposure to film.
Statistics
Results are expressed as meanϮSEM. Statistical significance was evaluated using repeated-measures ANOVA and Student's t test for unpaired data. Differences were considered significant at PϽ0.05. Membrane currents were measured from the zero current level and normalized to cell capacitance.
Results
Effect of AT 1 R-AS Treatment on Blood Pressure
A single intracardiac injection of LNSV-AT 1 R-AS to neonatal rats prevented the increase in blood pressure exclusively in SHR for at least 210 days after injection (Figure 1 ). The mean blood pressure was 36.6% lower in SHR treated with LNSV-AT 1 R-AS than in untreated SHR (128Ϯ12 versus 202Ϯ8 mm Hg, nϭ6; PϽ0.01). In addition, the mean blood pressure measured in LNSV-AT 1 R-AS-treated SHR was not significantly different from that of the normotensive WKY controls (128Ϯ12 versus 118Ϯ6 mm Hg, nϭ6; PϾ0.05). This effect was specific for LNSV-AT 1 R-AS treatment since treatment with LNSV alone had no significant effect on mean blood pressure compared with that in control SHR (192Ϯ7 versus 202Ϯ8 mm Hg, nϭ6; PϾ0.05). A nonsignificant 10-mm Hg decrease in blood pressure was observed in WKY treated with antisense, while LNSV alone did not significantly affect the blood pressure of WKY (nϭ6, data not shown). This decrease in blood pressure is similar to that observed with acute losartan treatment of WKY. 19 
Effect of LNSV-AT 1 R-AS Treatment on Voltage and Receptor-Dependent Renal Arteriolar Vascular Reactivity
Alterations in vascular contractile response are known to exist in SHR, but no one has investigated specifically the role of [Ca 2ϩ ] i in small arterioles of the kidney, which play a significant role in regulating peripheral resistance. 1 LNSV-AT 1 R-AS treatment prevented the alterations in voltage-and receptor-dependent renal arteriolar vascular reactivity measured in SHR (Figure 2 ). Enhanced contractile responses to both KCl (Figure 2A ) and Ang II ( Figure 2C ) were observed in the SHR. A significant leftward shift in the KCl and Ang II concentration-response relationships was observed in SHR when compared with WKY controls (Figure 2A and 2C) . The media effective concentrations (EC 50 ) for KCl and Ang II were 11.1Ϯ2.1 mmol/L and 19.7Ϯ2.8 nmol/L (nϭ24 rings from 6 animals) in the untreated SHR and 36.6Ϯ3.4 mmol/L and 76.4Ϯ3.3 nmol/L (nϭ24 rings from 6 animals) in the WKY, respectively. LNSV-AT 1 R-AS prevented the shift in the EC 50 for both KCl and Ang II ( Figure 2B and 2D) . The EC 50 for KCl and Ang II in the LNSV-AT 1 R-AS-treated SHR was 39.1Ϯ4.2 mmol/L and 68.7Ϯ4.2 nmol/L (nϭ24 rings from 6 animals), which was not significantly different from that of the WKY. Finally the EC 50 for KCl and Ang II in the LNSV-treated SHR was 21.1Ϯ3.8 mmol/L and 17.7Ϯ2.1 nmol/L (nϭ24 rings from 6 animals), which was not significantly different from that of the untreated SHR.
Effect of LNSV-AT 1 R-AS on L-Type Ca
2؉
Current Density
It has been previously demonstrated that L-type Ca 2ϩ current is increased in large conduit arteries of the SHR. 15 Figure 3 illustrates the characteristics of L-type Ca 2ϩ current in single cells isolated from renal resistance vessels of WKY and SHR. During voltage step depolarizations in the presence of block- ers of K ϩ current, an inward Ca 2ϩ current was observed. This Ca 2ϩ current was L-type because it is completely inhibited by the dihydropyridine nifedipine (100 nmol/L, data not shown). It is quite evident from the current recordings ( Figure 3A ) and the current-voltage relationships ( Figure 3B , nϭ21 cells from 6 animals) that Ca 2ϩ current density in the cells from the SHR was increased when compared with cells from the WKY. This increase in Ca 2ϩ current was not evident in SHR treated with LNSV-AT 1 R-AS but was apparent in those treated with LNSV alone (Figure 3A and 3B) .
A number of reasons for the difference in Ca 2ϩ current may exist. First, this difference in Ca 2ϩ current density could be due a difference in cell size. It should be noted that the cell capacitance was not significantly different among all of the groups tested (WKY 28Ϯ3 pF, SHR 27Ϯ2 pF, SHR-LNSV-AT 1 R-AS 29Ϯ2 pF, SHR-LNSV 26Ϯ3 pF). Second, the difference in Ca 2ϩ current density may be due to alterations in the properties of voltage-dependent activation or inactivation. However, the Figure 4 ) using an antibody that recognized ␣ 1C Ca 2ϩ channel proteins illustrated that when normalized to ␤-actin, there was no increase in the number of L-type Ca 2ϩ channels in the SHR renal resistance arterioles when compared with those in the WKY. Administration of LNSV-AT 1 R-AS did not alter these data.
Effect of LNSV-AT 1 R-AS on Voltage-and Receptor-Dependent Changes in [Ca 2؉ ] i
Because the KCl and Ang II concentration-response relationship was shifted to the left in the SHR and this was prevented in the SHR treated with LNSV-AT1R-AS, we wanted to examine next whether alterations in intracellular Ca 2ϩ handling would be prevented using LNSV-AT 1 R-AS gene therapy. We have previously shown that basal and Ang IIstimulated increases in [Ca 2ϩ ] i were greater in renal arteriolar cells of the SHR when compared with WKY. 17 Figure 5 shows the change in [Ca 2ϩ ] i when renal resistance artery cells were challenged with KCl (30 mmol/L, Figure [ pF; SHRϩLNSV, 28 pF). B, There was no significant difference in current density of the cells from the WKY (nϭ21 cells from 6 animals) and SHRϩAT 1 R-AS (nϭ18 cells from 6 animals). However, the Ca 2ϩ current density for both the peak and sustained components was significantly greater in the SHR (nϭ25 cells from 6 animals) and SHRϩLNSV (nϭ20 cells from 6 animals). (nϭ162 cells from 4 animals). These increases in [Ca 2ϩ ] i were completely prevented when SHR were treated with LNSV-AT 1 R-AS (nϭ134 cells from 4 animals). There was no significant difference between SHRϩLNSV and the untreated SHR (nϭ122 cells from 4 animals). When experiments were performed in zero external calcium, all of the KCl-dependent contractions were abolished. However, Ang II still produced a greater peak [Ca 2ϩ ] i measurement in renal arteriolar cells from the SHR than from the WKY. These increases in [Ca 2ϩ ] i were completely prevented when SHR were treated with LNSV-AT 1 R-AS (data not shown). These data support the conclusion that LNSV-AT 1 R-AS gene therapy prevents altered Ca 2ϩ handling in hypertension.
AT 1 R-AS Gene Delivery Does Not Affect
Discussion
The results of this study are novel and demonstrate for the first time that the delivery of AT 1 R-AS prevents (1) the development of hypertension for up to 210 days and (2) the alterations in [Ca 2ϩ ] i homeostasis associated with hypertension in the SHR. Neonatal SHR that were given a single intracardiac injection of AT 1 R-AS did not develop (1) elevated blood pressure; (2) increased voltage-dependent Ca 2ϩ influx, as measured by an increase in Ca 2ϩ current density, across renal vascular smooth muscle membranes; (3) an increase in Ang II-mediated Ca 2ϩ influx; or (4) increased Ca 2ϩ release from sarcoplasmic reticulum. These findings, along with our previous observations, 14 suggest that interruption of the RAS with virally mediated gene delivery may be used to prevent hypertension and its associated renal pathophysiological complications.
The kidneys, which exquisitely control blood pressure and extracellular fluid volume and ultimately renal blood flow, participate in the development of essential hypertension. The results of earlier renal transplant studies in humans and animals suggest that in a proportion of hypertension cases there exist structural or functional alterations in the kidney. 16 An elevation in renal vascular tone and therefore renal vascular resistance exists in hypertension; this elevation may be due to a number of factors including (1) an enhanced contractile sensitivity to vasoactive agonists, (2) an impaired endothelium-dependent relaxation, (3) an increased Ca 2ϩ transport across vascular smooth muscle membranes, (4) an altered ion channel activity in vascular smooth muscle, and (5) smooth muscle hypertrophy or hyperplasia. 1 One fundamental reason why renal vascular resistance may be increased in hypertension is an altered ion channel function in vascular smooth muscle cells. Tonic changes in membrane potential and thus Ca 2ϩ influx regulate contractile tone of resistance arterioles. A number of reports show that Ca 2ϩ current density is increased in the SHR model of hypertension. 15 However, these studies have been in conduit arteries, which play a less significant role in the regulation of peripheral resistance. Here we show that not only is Ca 2ϩ current density increased in the SHR, but there is no change in the level of Ca 2ϩ channel protein in renal resistance vessels. These data suggest that there may be an altered intracellular regulation of L-type Ca 2ϩ channels that may underlie the enhanced Ca 2ϩ influx in vascular smooth muscle cells and increases in vascular resistance observed in the kidney in hypertension. It is possible that an increase in Ca 2ϩ influx could tend to load the sarcoplasmic reticulum with more Ca 2ϩ , enabling more to be released on challenge by a physiological stimuli. Here we show that this altered Ca 2ϩ handling by the sarcoplasmic reticulum can be prevented using AT 1 R-AS. This prevention would underlie the shift of the concentration-response curve back to normal with AT 1 R-AS treatment. Physiologically, this would tend to decrease the amount of vascular tone in the kidney for a given concentration of circulating Ang II.
Finally, cardiovascular ultrastructural changes are a major risk factor for morbidity and mortality in hypertension, and Ang II has been speculated to play a role in the increased vascular hypertrophy and/or hyperplasia in hypertension. Could gene therapy delivery systems interrupting the RAS be used to control the vascular remodeling/hypertrophy seen in various forms of hypertension? We have previously shown that AT 1 R-AS treatment could prevent the observed increase in perivascular fibrosis and ventricular hypertrophy in the SHR. 14 Liao et al 21 have demonstrated that receptordependent stimulation of a Ca 2ϩ -dependent PKC isoform activates mitogen-activated protein kinase (MAPK) and thus regulates vascular smooth muscle cell growth. The above associated complications occur on a long-term basis, and their cellular mechanisms of action appear to be a [Ca 2ϩ ] idependent process. Therefore, interference in the RAS using gene therapy may be an important pharmacological target to block vascular ultrastructural and remodeling changes in hypertension. Is antisense gene therapy targeting the RAS a therapeutic step forward? In short, the answer is yes. It results in the prevention of the increase in mean blood pressure and the associated pathophysiological impairments in hypertension. It also offers an alternative to the compliance problem and complications of vascular and target-organ injury. Finally, AT 1 R-AS therapy does not produce a significant increase in plasma Ang II levels compared with losartan, the AT 1 R antagonist. 18 Therefore, AT 1 R-AS gene delivery and therapy does have prolonged antihypertensive effects without the possible adverse side effects produced by traditional pharmacological therapies. One caveat of the approach taken in this study is that AT 1 R-AS gene delivery prevents the pathophysiological complications occurring with the development of hypertension. Moreover, this type of gene delivery/therapy depends on the identification of genetic determinants of hypertension or on the demonstration of reliable prehypertensive risk factors before it can be used in human trials. Another approach currently being investigated in our laboratory is to develop the next generation of viral vectors, which would increase the feasibility of delivering RAS-relevant genes into the adult SHR to reverse pathophysiological complications observed in hypertension. Preliminary studies show that delivery of RAS-relevant antisense into the adult SHR reverses the increase in blood pressure as well as the differences in excitation-contraction coupling observed in hypertension (C.H. Gelband, unpublished observations, 1998). In summary, gene therapy holds promise in single-dose, long-term treatment for hypertension.
